Education
About Us
Working with TipRanks
Follow Us
Genmab A/S (GMAB)
NASDAQ:GMAB
GMAB Stock Chart & Stats
$33.17
-$0.14(-0.65%)
At close: 4:00 PM EST
$33.17
-$0.14(-0.65%)
Day’s Range― - ―
52-Week Range$17.24 - $33.65
Previous CloseN/A
Volume229.76K
Average Volume (3M)2.17M
Market Cap
$20.58B
Enterprise Value$9.96B
Total Cash (Recent Filing)$18.37B
Total Debt (Recent Filing)$937.88M
Price to Earnings (P/E)16.2
Beta0.53
Next Earnings
Nov 06, 2025EPS Estimate
0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.54
Shares Outstanding642,063,500
10 Day Avg. Volume2,709,101
30 Day Avg. Volume2,172,723
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.48
Enterprise Value/Revenue0.44
Enterprise Value/Gross Profit0.46
Enterprise Value/Ebitda1.30
Forecast
1Y Price Target
$40.60Price Target Upside22.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Market PotentialPetosemtamab's market opportunity in head and neck cancer alone could exceed $3B annually.
Sales PerformanceDARZALEX's latest reported worldwide net sales came in higher than prior estimates and the consensus estimate.
Strategic AcquisitionMerus Acquisition Bolsters Genmab's Late-Stage Pipeline.
Bears Say
Acquisition CostsThe $8B deal is sizable and carries significant operating expenses and interest expense dilution in the initial years following the acquisition.
Debt ConcernsConcerns exist regarding the debt required to complete the Merus acquisition, influencing the current flat trading of Genmab shares.
Sales RiskRisks include slowing DARZALEX sales, failure to obtain DARZALEX label extensions, and negative readouts from DARZALEX trials.
Genmab News
GMAB FAQ
What was Genmab A/S’s price range in the past 12 months?
Genmab A/S lowest stock price was $17.23 and its highest was $33.65 in the past 12 months.
What is Genmab A/S’s market cap?
Genmab A/S’s market cap is $20.58B.
When is Genmab A/S’s upcoming earnings report date?
Genmab A/S’s upcoming earnings report date is Nov 06, 2025 which is in 19 days.
How were Genmab A/S’s earnings last quarter?
Genmab A/S released its earnings results on Aug 07, 2025. The company reported $0.542 earnings per share for the quarter, beating the consensus estimate of $0.399 by $0.143.
Is Genmab A/S overvalued?
According to Wall Street analysts Genmab A/S’s price is currently Undervalued.
Does Genmab A/S pay dividends?
Genmab A/S does not currently pay dividends.
What is Genmab A/S’s EPS estimate?
Genmab A/S’s EPS estimate is 0.48.
How many shares outstanding does Genmab A/S have?
Genmab A/S has 642,063,500 shares outstanding.
What happened to Genmab A/S’s price movement after its last earnings report?
Genmab A/S reported an EPS of $0.542 in its last earnings report, beating expectations of $0.399. Following the earnings report the stock price went up 5.486%.
Which hedge fund is a major shareholder of Genmab A/S?
Currently, no hedge funds are holding shares in GMAB
Genmab Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$40.60 (22.40% Upside)
$40.60 (22.40% Upside)
Blogger Sentiment
Bullish
GMAB Sentiment 66%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 425.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 26.1%
Last 30 Days ▲ 26.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
44.91%
12-Months-Change
Fundamentals
Return on Equity
26.08%
Trailing 12-Months
Asset Growth
16.47%
Trailing 12-Months
Company Description
Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
GMAB Company Deck
GMAB Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial performance and promising clinical trial results, particularly for EPKINLY and Rina-S. The company is strategically investing in its pipeline and expanding its market presence. However, challenges such as the discontinuation of HexaBody-OX40 and potential regulatory hurdles were noted.View all GMAB earnings summariesGMAB Stock 12 Month Forecast
Average Price Target
$40.60
▲(22.40% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.23% Mutual Funds
<0.01% Other Institutional Investors
98.89% Public Companies and Individual Investors